

CHIMERIC TO PRESENT AT NWR VIRTUAL INVESTOR CONFERENCE

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical stage cell therapy company focused on bringing the promise of cell therapy to patients with cancer, is pleased to announce it will present at the NWR Virtual Investor Conference on Thursday 18 March 2021.

The Company invites shareholders and investors to see Chimeric Therapeutics Executive Chairman Paul Hopper and COO Jennifer Chow present an update at 9:00am AEDT on 18 March 2021.

Event: NWR Communications Virtual Investor Conference
Presenting: Paul Hopper (Executive Chairman, Chimeric) and Jennifer Chow (COO, Chimeric)
Time: Thursday 18 March 2021, 9:00am AEDT

Investors are invited to submit questions prior to the event to: matt@nwrcommunications.com.au

Investors can register online to view the presentation here:
https://us02web.zoom.us/webinar/register/WN_ai6XaBqMS8mwZKsG5FdbKA

For more information on the conference click here: <https://nwrconference.webflow.io/>

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for patients with cancer.

Chimeric believes that cellular therapies have the potential to cure cancer and that by combining the Company’s expertise in the development and commercialisation of cell therapies with the world’s most innovative scientists and science, Chimeric will be able to bring the promise of cell therapy to life for more patients.

Chimeric Therapeutics is currently in a phase 1 clinical trial for its lead asset, CLTX-CAR T.

CLTX-CAR T is a novel and promising CAR T therapy for the treatment of patients with Glioblastoma (GBM), developed by scientists at the City of Hope Medical Centre in California. CLTX-CAR T technology incorporates chlorotoxin (CLTX), a peptide derived from scorpion toxin, as a novel CAR tumor recognition domain. Potent antitumor activity against glioblastoma (GBM) has been established in preclinical models while CLTX-CAR T cells were not shown to exhibit off-tumor recognition of normal human or murine cells/tissues, supporting a potential optimal safety profile.

Chimeric Therapeutics is now actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

CONTACT

Investors

Paul Hopper

Executive Chairman

P: +61 406 671 515

E: paulhopper@lifescienceportfolio.com

W: www.chimerictherapeutics.com

Media

Matthew Wright

NWR Communications

P: +61 451 896 420

E: matt@nwrcommunications.com.au